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Abstract: To review the current treatment of chronic dry eye syndrome, focusing on 
cyclosporine A (CsA), a systematic literature search was performed using PubMed databases 
in two steps. The ﬁ  rst step was oriented to articles published for dry eye. The second step was 
focused on the use of CsA in dry eye. A manual literature search was also undertaken based 
on citations in the published articles. The knowledge on the pathogenesis of dry eye syndrome 
has changed dramatically during the last few years. Inﬂ  ammation and the interruption of 
the inﬂ  ammatory cascade seem to be the main focus of the ophthalmologic community in the 
treatment of dry eye, giving the anti-inﬂ  ammatory therapy a new critical role. The inﬁ  ltration 
of T-cells in the conjuctiva tissue and the presence of cytokines and proteasis in the tear ﬂ  uid 
were the main reason introducing the use of immunomodulator agents such as corticosteroids, 
cyclosporine, and doxycicline in order to treat dry eye syndrome. CsA emulsion is approved 
by the FDA for the treatment of dry eye, while clinical trials of this agent have demonstrated 
efﬁ  cacy and safety of CsA. CsA seems to be a promising treatment against dry eye disease. 
New agents focused on the inﬂ  ammatory pathogenesis of this syndrome in combination with 
CsA may be the future in the quest of treating dry eye. More studies are needed to determine 
the efﬁ  cacy, safety, timing, and relative cost/effect of CsA.
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Introduction
Epidemiology
Dry eye is a frequent disease. Among dry eye patients over the age of 65 in the US, 
25% reported using artiﬁ  cial tears on a frequent basis and 73% visited an eye care 
professional during the previous year for this condition (Shein et al 1997).
It is estimated that approximately 7.1 million people over the age of 40 in the US 
experience symptoms of ocular irritation due to dry eye syndrome (Pﬂ  ugfelder 2004), 
while more than 6% of the population over the age of 40 and more than 15% of the 
population over the age of 65 suffer from dry eye (Bjerrum 1997; Schein et all 1997; 
McCarty et all 1998).
The estimated global sales of artiﬁ  cial tears exceeded US$540 million annually in 
2002 (Harmon and Murphy 2003), whereas the total annual healthcare cost of 1,000 dry 
eye syndrome sufferers managed by ophthalmologists ranged from US$0.27 million 
(95% CI: $0.20; US$0.38 million) in France to US$1.10 million (95% CI: US$0.70; 
US$1.50 million) in the UK. A large proportion of dry eye patients is either self-treated 
or managed by their general practitioner (Clegg et al 2006).
Diagnosis of dry eye
Clinically there is a plethora of irritation symptoms associated with dry eye such 
as ocular burning, stinging, scratchiness, soreness, photophobia, blurred vision and 
foreign body sensation. Tear ﬁ  lm stability can be assessed with the ﬂ  uorescein tear Clinical Ophthalmology 2008:2(4) 830
Kymionis et al
break-up time test, measuring the interval in seconds between 
a complete blink and the ﬁ  rst appearing dry spot or discon-
tinuity in the precorneal ﬁ  lm. Aqueous tear production is 
measured more commonly with Shirmer test, calculating 
the length in millimeters that a folded ﬁ  lter paper strip 
placed in the lower lid wets during a 5-minute test period. 
There are two ways to perform this test: a) Shirmer test I is 
performed without topical anesthesia, which evaluates better 
the ability of the ocular gland to respond to ocular surface 
stimulation; b) Shirmer test II (or Basic Secretion test) which 
is performed after topical anesthesia, evaluating better the 
basal tear secretion. Meibonian gland disease is diagnosed 
by biomicroscopic recognition of pathological signs such as 
ductal oriﬁ  ce metaplasia, reduced expressibility of meibo-
nian gland secretions, increased viscosity of the expressed 
secretion and dropout of glandular acini. Conjunctival 
goblet cell density and epithelial morphology can be directly 
evaluated by cytology. The most practical clinical method 
for assessing the severity of dry eye is the ocular surface dye 
staining. Fluorescein, rose Bengal and lissamine green are 
use as diagnostic dyes for evaluating the staining. Fluorescein 
staining occurs when the epithelial barrier is disrupted, 
due to the loss of the epithelial cells, is well tolerated by 
patients and evaluates better corneal staining. Rose Bengal 
and lissamine green stain the conjunctiva more brightly than 
the cornea. Rose Bengal stains devitalized epithelial cells 
or cells without protective mucus layer, but cause transient 
irritation after installation. Lissamine green dyes degenerated 
or dead cells and produces less irritation than rose Bengal 
(Plufelder 2006).
However, many times symptoms and signs are not always 
speciﬁ  c and are often underestimated by the patient or under 
diagnosed by ophthalmologist (Schein et al 1997; Afonso 
et al 1999; Lin et al 2003).
Deﬁ  nitions and classiﬁ  cations
of dry eye
In 1995 the National Eye Institute workshops, deﬁ  ned dry 
eye as “a disorder of the tear ﬁ  lm due to tear deﬁ  ciency 
or excessive evaporation that causes damage to the 
interpalpebral ocular surface and is associated with symptoms 
of discomfort” (Lemp 1995). In the Definition and 
Classiﬁ  cation Subcommittee of the international Dry Eye 
Workshop in 2007, a new contemporary deﬁ  nition of dry 
eye disease was reported, supported within a comprehensive 
classiﬁ  cation framework. In accordance with the committee, 
dry eye was deﬁ  ned as a multifactorial disease of the tears 
and ocular surface that results in symptoms of discomfort, 
visual disturbance, and tears ﬁ  lm instability with potential 
damage to the ocular surface. It is accompanied by increased 
osmolarity of the tear ﬁ  lm and inﬂ  ammation of the ocular sur-
face. The committee recommended a three part classiﬁ  cation 
system. The ﬁ  rst part was etiopathogenic, illustrating the 
multiple causes of dry eye. In this group dry eye was divided 
in two principal categories: aqueous deﬁ  cient (Sjogren or 
non-Sjogren related) and evaporative (intrinsic or extrinsic 
causes); the second was mechanistic, showing the way each 
cause may act through a common pathway (tear hyperosmo-
larity and tear ﬁ  lm instability); the third part was based on 
the severity of the disease (four groups correlated to visual 
symptoms, conjuctival injection, conjunctival staining, cor-
neal staining, corneal/tears signs, lid/meibonian glands, tear 
break-up time, and Shirmer test), providing a rational basis 
for therapy (DEW 2007).
In 2006 in a Delphi panel approach to treatment 
recommendations by 17 international specialists on dry 
eye syndrome, a new term was proposed for dry eye 
disease: dysfunctional tear syndrome (DTS). In our study 
the most commonly used diagnostic test reported by 
more than half of the panelists for evaluating probable 
dry eye were ﬂ  uorescein staining (100%), tear break up 
time (94%), Shirmer test (71%), and rose Bengal staining 
(65%). Panelists agreed on three particular relevant 
symptoms and historical elements to be considered: ocular 
discomfort (itch, scratch, burn, foreign body sensation, 
and/or photophobia), tear substitute requirements, and 
visual disturbance. There was a consensus that most 
cases of DTS have an inflammatory basis that either 
triggers or maintains the inﬂ  ammation. However, there 
was an agreement on the difﬁ  culty in clearly identifying 
inﬂ  ammation in most patients and consequently the panel 
agreed to subclassify the disease as either DTS with 
clinically apparent inﬂ  ammation or DTS without clinically 
evident inﬂ  ammation (Behrens et al 2006).
Pathogenesis
The ocular surface and the lacrimal gland are considered, 
studied, and treated as an integrated functional unit 
interconnected by neural sensory/autonomic reﬂ  ex arcs. 
Sensory afferent nerves, which enervate the ocular surface, 
traffic along the ophthalmic branch of the trigeminal 
nerve to the Pont area of the central nervous system. 
After received inputs from cortical areas (emotional 
central nervous centers), efferent nerves, consisting of 
parasympathetic ﬁ  bers traveling in the facial nerve and 
of sympathetic ﬁ  bers from the paraspinal sympathetic Clinical Ophthalmology 2008:2(4) 831
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chain, lead to the main and the accessory lacrimal gland 
(Pﬂ  ugfelder et all 2000).
Over recent years, inﬂ  ammation has been shown to be 
the key in the pathogenesis of this syndrome, as it seems to 
be the cause and the consequence of dry eye. Regardless 
of the triggering factor, a vicious cycle of inﬂ  ammation 
may be developed on the ocular surface in patients with 
dry eye. A glandular dysfunction creating tear deﬁ  ciency or 
instability could irritate the surface of the eye and promote 
inﬂ  ammation, which increases further the tear deﬁ  ciency 
(Jones et all 1998). The results are antigen presentation and 
cytokine secretion by the epithelial cells of the lacrimal gland 
which promote the activation of the T-cells lymphocytes. 
Finally, the T-cells secrete pro-inﬂ  ammatory cytokines, 
increasing further the level of inﬂ  ammation (Meggs 1993; 
Mircheff et al 1998; Gao et al 1998). Consequently, the tears 
will contain cytokines. The ocular surface reacts, promoting 
inﬂ  ammatory response which consists of inﬂ  ammatory cell 
inﬁ  ltration, epithelial activation, increased concentrations 
of cytokines and other inﬂ  ammatory factors, and increased 
activity of matrix-degrading enzymes (Baudouin et al 
1997; Tishler et al 1998; Afonso et al 1999; Pﬂ  ugfelder 
1999; Pﬂ  ugfelder 2000; Sobrin et al 2000). This knowledge 
concerning the inﬂ  ammation pathogenic mechanism in dry 
eye syndrome alters also the therapeutic approach against 
this syndrome which is now based on anti-inﬂ  ammatory 
agents.
Therapy
The therapy of dry eye depends on its severity. Based on the 
most recent concept, the armamentarium used to control dry 
eye comprises a large range of therapeutic strategies.
Modification of the environmental conditions that 
increase tear evaporation (eg, low humidity), avoiding the 
use of systemic medications with anticholinergic side effects 
(eg, antihistamines), occlusion of the lacrimal canaliculi 
(punctal occlusion), stimulation of tears production (oral 
secretagogues pilocarpine), and minimization of corneal 
exposure (tarsorrhaphy, gas permeable contact lenses). 
Although these treatment options are very useful, all of them 
are considered to be symptomatic therapeutic approaches 
and not pathogenic.
Artiﬁ  cial tears
Artiﬁ  cial tears provide temporal improvement in eye irritation 
and blurred vision symptoms, visual contrast sensitivity, tear 
break up time, and ocular surface dye staining. (Gifford et al 
2006; Ousler et al 2007). Artiﬁ  cial tears contain polymers 
such as cellulose esters, polyvinyl alcohol, and povidone, 
which determine their viscosity, shear properties, retention 
time, and adhesion to the ocular surface. Gels have longer 
retention times than artiﬁ  cial tear solutions (Bron et al 1998; 
Wilson et al 1998).
Anti-inﬂ  ammatory therapy
Anti-inﬂ  ammatory therapy is considered to be the ﬁ  rst 
“causative therapeutic approach” in the treatment of dry eye, 
since its objective is to interrupt the inﬂ  ammatory cascade. 
Topical corticosteroids, tetracyclines, and cyclosporine 
A (CsA) are the drugs used in the anti-inﬂ  ammatory therapy 
of dry eye.
Corticosteroids
Topical corticosteroids can be used in order to decrease 
ocular surface inﬂ  ammation inhibiting MMPs (matrix 
metalloproteinasis), inﬂ  ammatory cytokines and adhesion 
molecule production. They demonstrate satisfactory results 
as pulse therapy. In a retrospective study which included 
Sjogren syndrome patients with keratoconjunctivitis 
sicca (KCS), the administration of 1% solution of 
methylprednisolone (3 times a day for 2 weeks) relieved 
symptoms in all patients (Marsh and Pflugfelder 
1999). Corticosteroids should not be administered for 
long-term use owing to the side effects they can provoke 
(steroid response increasing of IOP, cataractogenesis). 
Corticosteroids with minimal potential to raise IOP 
(ﬂ  uorometholone and loteprendol etabonate) could be 
considered a safer approach. A randomized, double-masked, 
placebo-controlled study of loteprednol etabonate and its 
vehicle was conducted on 64 patients with delayed tear 
clearance and KCS. After 2 and 4 weeks of treatment, there 
was no change in IOP in the corticosteroid-treated group. 
Patients with the most severe inﬂ  ammatory signs at entry 
showed a signiﬁ  cantly greater decrease in central corneal 
ﬂ  uorescein staining scores while a signiﬁ  cant decrease in 
inferior bulbar conjunctival hyperemia was demonstrated 
after 2 weeks (Plugfelder et al 2004).
Tetracyclines
Tetracyclines have also a variety of anti-inflammatory 
properties such as inhibition of MMPs and interleukine-I (IL-I) 
production (Amin et al 1996; Shlopov et al 1999). Orally 
administrated they decrease ocular surface symptoms in 
patients with ocular rosacea (Frucht-Pery et al 1993; Akpek 
et al 1997) and in patients with recurrent corneal epithelial 
erosions (Hope-Ross et al 1994).Clinical Ophthalmology 2008:2(4) 832
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The best tolerated tetracycline is doxycycline, which 
is effective in doses of 20–50 mg orally twice a day for a 
treatment up to 4 weeks (Plugfelder 2004).
Cyclosporine A
Today CsA seems to represent a very promising treatment 
against dry eye syndrome since it is the ﬁ  rst agent focused on 
the pathogenesis of this disease. It can be used for long term 
without presentation of the adverse effects characterizing the 
other anti-inﬂ  ammatory agents.
Methodology
A systematic literature review was performed using PubMed 
databases in two steps. The ﬁ  rst step was oriented to articles 
published for dry eye. The second step was focused on the 
use of CsA in dry eye. The search strategy was not limited 
by year of publication. A manual literature search was also 
undertaken based on citations in the published articles.
Results
Cyclosporine A is a fungal-derived peptide that inhibits 
T-cell activation and consequently inhibits the inﬂ  amma-
tory cytokine production (selective inhibition of IL-I). In 
addition, CsA inhibits apoptosis by blocking the opening 
of the mitochondrial permeability transition pore (MPTP) 
(Matsuda and Koyasu 2000) and by increasing the density 
of conjuctival goblet cells (Kunert et al 2002).
In the US, CsA is commercially distributed as Restasis®. 
This ophthalmic emulsion (0.05% cyclosporine [Allergan, 
Inc. Irvine, CA, USA]) is preservative free packaged in 
unit-dose vials. Restasis has been a prescription drug in the 
US since April 2003 when it was approved by the FDA for 
patients whose tear production is presumed to be suppressed 
due to ocular inﬂ  ammation associated with KCS.
CsA was used for years routinely as an oral immunosup-
pressor for organ transplantation. Its action is non toxic and 
reversible after the treatment. In ophthalmology prior to dry eye 
treatment, CsA was used also for the treatment of severe pos-
terior segment inﬂ  ammations, when administered systemically 
(iv) or orally (Masuda et al 1989). Systemically CsA was also 
used for the treatment of peripheral ulcerative keratitis associ-
ated with Wegener’s granulomatosis, in severe Graves’s oph-
thalmopathy, and for the prevention of the recurrence of graft 
rejection after keratoplasty (Prummel et al 1989; Nussenblatt 
et al 1991; Georganas et al 1996; Reinhard et al 1997).
All these indications were the result of CsA’s 
pharmacokinetics, since extraocular and intraocular 
tissues can be reached by this agent through the systemic 
pathway after oral administration. In fact, after oral daily 
administration of 5 mg/kg daily, the concentration of 
CsA was measured to be 25–75 μg/mL in human tears 
(BenEzra et al 1990); systemic administration may be 
accompanied by severe side effects such as nephrotoxity 
and hypertension (Mihatsch et al 1998). As a result 
topical ocular delivery was proposed as a good alterna-
tive. Despite its poor intraocular penetration, topical CsA 
has been successfully used in dry eye syndrome. Another 
pharmacokinetic limitation was that CsA could not be 
prepared in a formulation based on aqueous ophthalmic 
vehicles because of both its hydrophobicity and its low 
aqueous solubility. Therefore, the agent was dissolved in 
vegetable oils (Lallemand et al 2003).
The potential of CsA for treating dry eye syndrome and its 
clinical expression KCS was initially tested in 1989 in dogs 
affected with spontaneous canine KCS. Tear production was 
increased. CsA caused marked regression of chronic corneal 
neovascularization and granulation even in eyes in which 
lacrimation failed to improve. Additional beneﬁ  ts of topical 
cyclosporine were: reduced mucopurulent conjunctivitis, 
rapid healing of non-healing corneal ulcers, and reduced 
dependence on frequent topical treatments of KCS (Kaswan 
et al 1989). The experimental results were veriﬁ  ed by other 
similar studies in dogs (Morgan and Abrams 1991; Olivero 
et al 1991; Izci et al 2002). Furthermore, experiments in a 
mutant mouse model used for primary Sjogren’s syndrome 
has demonstrated the anti-inflammatory effect of both 
topical and orally administrated CsA on the lacrimal gland 
(Tsubota et al 1998), whereas other experiments in mice 
suggested that CsA accelerates tear secretion by releasing 
neurotransmitters from sensory nerve endings, which interact 
with the parasympathetic nerves (Yoshida et al 1999). Similar 
conclusions were also demonstrated in studies with rabbits 
(Toshida et al 1998).
The use of CsA delivered as ointment or oil suspension 
was then studied for treatment of humans KCS. Topi-
cal CsA 2% in olive oil was investigated for its possible 
immunoregulatory role on the dry eye state in patients 
with secondary Sjogren’s syndrome. Thirty eyes of 
15 patients were randomized to undergo treatment with 
topical cyclosporine in olive oil, while an other group of 
15 patients (30 eyes) received a placebo (which was the 
sterile olive oil used as a vehicle for the cyclosporine). 
There was a signiﬁ  cant increase in the break-up time and a 
signiﬁ  cant decrease in rose Bengal staining score between 
the cyclosporine and control groups at the end of the 2-month 
study period (Gunduz and Ozdemir 1994). Laibovitz et al Clinical Ophthalmology 2008:2(4) 833
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(1993) conducted a study in which patients with KCS 
underwent 6 weeks of treatment with either cyclosporine 
1% ophthalmic ointment or placebo, followed by 6 weeks 
of the alternative treatment. Cyclosporine ointment was 
associated with initial mild to moderate redness, itching, and 
burning that returned to baseline levels within 1–2 weeks. 
Rose Bengal results and results of 4 subjective (patient diary) 
efﬁ  cacy parameters favored cyclosporine: foreign body 
sensation, overall symptoms, hours of symptom control per 
day, and overall effectiveness. No systemic adverse events 
or laboratory abnormalities occurred. Subsequently, CsA for 
treating KCS in patients with dry eye was evaluated in large 
multi-center randomized double-masked FDA clinical trials. 
An FDA phase 2, randomized, multicenter, double masked, 
parallel-group, dose-response clinical trial compared 4 dif-
ferent dose of CsA (CsA ophthalmic emulsion 0.05%, 0.1%, 
0.2%, 0.4%) administrated twice daily into both eyes of 129 
patients and 33 patients treated with a vehicle for 12 weeks, 
followed by a 4-week post-treatment observation period. In a 
subset of 90 patients with moderate to severe KCS, CsA was 
found to decrease rose Bengal staining, superﬁ  cial punctuate 
keratitis, and symptoms of ocular discomfort. Although there 
was no clear dose-response relationship, CsA 0.1% seemed 
to produce the most consistent improvements in subjective 
and objective end points, whereas CsA 0.05% demonstrated 
the most consistent improvement in patients’ symptoms. 
All treatments were well tolerated by patients (Stevenson 
et al 2000).
In the FDA phase 3 study group, 2 independent multicenter, 
randomized, double-masked, parallel group, 6-month, vehicle 
control clinical trials compared the efﬁ  cacy and safety of 
CsA in 877 patients with deﬁ  ned moderate to severe dry eye 
disease. The patients were treated twice daily with either CsA 
0.05% or 0.1%, or vehicle (292 to 293 patients in each group). 
The results of these two trials were combined for analysis. 
There was no dose-response effect. A treatment effect was 
observed after ﬁ  rst month of treatment and increased over the 
6-month follow-up period. Patients treated with CsA (0.05% 
or 0.1%) showed signiﬁ  cantly greater improvements than 
vehicle in 2 objective signs (corneal ﬂ  uorescein staining and 
categorized Shirmer values). CsA 0.05% treatment also dem-
onstrated signiﬁ  cantly greater improvements in three subjec-
tive measures of dry eye (blurred vision, need for concomitant 
artiﬁ  cial tears, and physician’s evaluation of global response 
to treatment). After 6 months of treatment there was a sta-
tistically signiﬁ  cant improvement from baseline within both 
groups in Shirmer tear test obtained with anesthesia, whereas 
in those obtained without anesthesia there was a statistically 
signiﬁ  cant improvement from baselines within all treatment 
groups but no statistically signiﬁ  cant differences among the 
groups. The most common treatment-related adverse effect 
was burning eye sensation (15% for CsA 0.05% group and 
17% for CsA 0.1% group). Patients receiving the vehicle 
had a lower frequency of burning eye sensation (7%). Other 
common adverse events (reported by 3% of patients) were 
stinging eye, eye discharge, foreign body sensation, con-
junctival hyperemia, visual disturbance, and eye pain (Sall 
et al 2000).
A multicentered, non-randomized, open label extension 
study of the two previous phase 3 clinical trials, evaluated 
the safety and efﬁ  cacy of CsA 0.1% ophthalmic emulsion 
over 1–3 years in moderate to severe dry eye disease patients. 
In 412 patients previously dosed for 6–12 months with CsA 
0.05% or 0.1%, CsA 0.1% was instilled twice daily for up to 
3 consecutive 12-month periods. For the duration of almost 
all the 20-month treatment, improvements in objective and 
subjective measures of dry eye were modest. The changes 
in corneal staining and Shirmer scores were not statistically 
signiﬁ  cant. Treatment-related adverse effects were found 
in 22% of patients. The most common were burning eye, 
stinging eye, and conjunctival hyperemia, but only 2 patients 
reported these symptoms as severe. In a survey of patients 
receiving CsA during a 12-month treatment period, most 
patients reported that during the ﬁ  rst clinical trial preceding 
this study, their symptoms began to resolve after the ﬁ  rst 
3 months. Although 85% of respondents continued to use 
artiﬁ  cial tears, their frequency decreased from 7.6 times per 
day to 3.8 times per day. 95.2% of respondents said that they 
would continue taking CsA after the study and 98% would 
recommend it to other patients. A 2 line loss of visual acuity 
was found in 13% of patients, whereas only 5% showed a 
gain of 2 lines (Barber et al 2005).
The use of CsA for the treatment of dry eye was also 
tested in a variety of situations correlated with this syndrome. 
It is well known that LASIK, despite its positive attributes 
in keratorefractive surgery, can induce dry eye syndrome 
in some patients (Aras et al 2000; Battat et al 2001; Toda 
et al 2001; Nassaralla et al 2003). Dry eye in patients that 
underwent LASIK seems to be a result of multifactorial 
processes such as decreased corneal sensation or alteration 
ocular surface and lacrimal gland function (Heigle and 
Plugfelder 1996; Linna et al 2000; Stern et al 2000). As a 
result, dry eye is considered to be almost a contraindication 
for LASIK surgery. A prospective clinical trial evaluated 
the safety and efﬁ  cacy of CsA 0.05% versus artiﬁ  cial tears 
in dry eye patients, from 1 month before to 3 months after Clinical Ophthalmology 2008:2(4) 834
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having LASIK. There were no statistically significant 
differences between baselines or between the two groups 
in response to ocular surface disease index questionnaire or 
best spectacle-corrected visual acuity. Treatment with CsA 
provided greater refractive predictability than artiﬁ  cial tears 
3 and 6 months after surgery (Salib et al 2006).
Rao and Rao (2006) assessed the efﬁ  cacy of cyclosporine 
in patients with dry eye associated with draft versus host 
disease after stem cells transplantation. After completing a 
3-month run-in period of using only artiﬁ  cial tears to control 
dry eye symptoms in both eyes, patients who failed to achieve 
adequate relief were instructed to instill topical cyclospo-
rine twice a day. Dry eye signs improved signiﬁ  cantly with 
cyclosporine treatment.
Based on its anti-inﬂ  ammatory action, topical CsA could 
also be used in a variety of other ocular surface disease 
such as vernal keratoconjutivitis (Pucci et al 2002), atopic 
keratoconjutivitis (Akpek et al 2004), ligneous conjutivitis 
(Rubin et al 1991), conjuctival linchen planus (Levell et al 
1992), and superior limbic keratoconjutivitis (Perry et al 
2003).
The concomitant use of cyclosporine with artiﬁ  cial tears 
has also been analyzed. Sal et al (2006) evaluated the efﬁ  cacy 
of marked artiﬁ  cial tears in relieving the signs and symptoms 
of dry eye when used as a supportive therapy to a cyclosporine-
based ophthalmic emulsion in a 6-month randomized investi-
gator masked parallel study of 61 patients. The patients were 
divided in 3 groups; in the ﬁ  rst two cyclosporine was com-
bined with a preservative-free carboxymethylcellulose 0.5% 
agent (Refresh Plus®, Allergan, Irvine, CA, USA) and with 
a hydroxypropyl-guar gellable lubricant eye drop (Systane®, 
Alcon laboratories, Inc., Fort Worth, TX, USA), whereas in 
the third group only Systane was used. Results indicated that 
the choice of concomitant therapy had signiﬁ  cant effects on 
outcome measures. The combination of Restasis-Systane 
was statistically signiﬁ  cantly better in reducing the signs 
and symptoms of dry eye than the combination of Restasis-
Refresh. In addition, Systane used alone was statistically 
signiﬁ  cantly better than Restasis-Refresh for 3 ocular symp-
tom frequency scales (burning, dryness, and scratchiness) and 
6 Likert acceptability questions. Finally, Restasis-Systane, 
compared with Systane alone, was not statistically different 
for any of the signs and symptoms measured except for the 
frequency of ocular blurring (Sal et al 2006).
Discussion
Although traditional symptomatic treatment still remains 
the method of choice, a more reasonable approach in the 
treatment of this syndrome would seem to be consider the 
inﬂ  ammatory mechanism of dry eye. The trend nowadays 
in patients with slight to mild episodic dry eye seems to be 
symptomatic therapy (eg, artiﬁ  cial tears, punctual occlusion), 
while in patients who already use artiﬁ  cial tears and who 
continue to have detectable ocular surface disease associated 
with inﬂ  ammatory signs, anti-inﬂ  ammatory agents seem to 
be the treatment of choice.
The use of CsA as anti-inﬂ  ammatory treatment for dry eye 
has advantages over corticosteroids because until now a) it 
has not demonstrated serious adverse effects; b) its action is 
reversible after the treatment; and c) it has a very low rate of 
systemic absorption. These pharmacokinetic characteristics 
are critical, since the possibility for long-term therapy in these 
patients is absolutely necessary for a chronic disease such 
as dry eye. In fact, the beneﬁ  ts of CsA begin after 1 moth 
of treatment and a therapy of at least 3 months seems to be 
indispensable.
Also other conditions associated with dry eye could 
beneﬁ  t from CsA. For example, refractive surgery of the 
cornea, most particularly LASIK, is almost contraindicated 
now in patients with dry eye. CsA treatment before and after 
surgery could help these patients obtain a surgical correction 
of their refractive error without the risk of dry eye. Graft 
versus Host disease cells after stem transplantation could 
also beneﬁ  t from CsA. Similar results were be found in 
other pathologies with an inﬂ  ammatory base, such as vernal 
kerato-conjunctivitis, atopic kerato-conjunctivitis, ligneous 
conjunctivitis, and superior limbic kerato-conjunctivitis.
Plugfelder (2004) reviewed anti inﬂ  ammatory therapy 
for chronic dry eye. He stated that dry eye is associated with 
ocular surface inﬂ  ammation that may further compromise 
tear secretion and cause ocular surface disease and irritation 
symptoms. Ocular surface inﬂ  ammation should be assumed 
in patients with an unstable tear ﬁ  lm and ocular surface 
epithelial disease that is detected by staining with diagnostic 
dyes. Of course, there is no diagnostic test available to gauge 
easily the level of inﬂ  ammation on the ocular surface. As 
a result, no ﬁ  rm recommendations can be made about the 
optimal timing for initiating anti-inﬂ  ammatory therapy in 
patients with dry eye. He concluded that it is reasonable 
to consider anti-inﬂ  ammatory therapy for patients using 
artiﬁ  cial tears who continue to have clinically detectable 
ocular surface disease, particularly if inﬂ  ammatory signs 
(for example, conjunctival redness) and irritation symptoms 
are present.
The Delphi panel in 2006 proposed treatment recommendation 
for dry eye on the basis of level of severity. They recommended Clinical Ophthalmology 2008:2(4) 835
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that topical administration of CsA must be given only when the 
disease is in severity level two, characterized by moderate to 
severe symptoms, tear ﬁ  lm signs, mild cornea punctuate stain-
ing, conjunctival staining, and visual signs.
However, a new treatment must take consider the 
relationship between cost and effect. Miljanovic et al (2007) 
measured the impact of dry eye syndrome on vision-related 
quality of life. They asked 190 participants with clinically 
diagnosed dry eye or severe symptoms and 399 without dry 
eye to complete a questionnaire, asking how much their 
everyday activities were limited by symptoms of dry eye 
and to what degree problems with their eyes limited their 
reading, driving, working at the computer, professional 
activities, and watching television. They concluded that 
dry eye syndrome is associated with a measurable adverse 
impact on several common and important tasks of daily 
living, further implicating this condition as an important 
public health problem deserving increased attention and 
resources. Clegg et al (2006) estimated the annual cost 
associated with the management of dry eye patients by 
ophthalmologists in France, Germany, Italy, Spain, Sweden, 
and the UK from the perspective of the health-care systems 
in the respective countries. They concluded that dry eye 
syndrome did not appear to impose a direct burden on the 
health care expenditure of the country investigated (Clegg 
et al 2006). However, among these countries CsA was used 
only in Germany for severe cases associated with Sjogren’s 
syndrome. CsA costs much more than other medicines and 
the economic impact of this medicine must be seriously 
considered in relation to its effect on dry eye, given that it 
not only substitutes for but also complements the existing 
treatments for dry eye.
It is likely that future clinical and epidemiological 
studies will provide more definitive recommendations 
about the timing, efﬁ  cacy, safety, and relative costs/beneﬁ  ts 
of anti-inﬂ  ammatory therapy with CsA for dry eye.
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